Evolution of clinical intestinal transplantation: Improved outcome and cost effectiveness by Abu-Elmagd, KM et al.
{ I 
, , 
; i I 
I 
I !, 
. ---.-----------------------------2!iiiiiii ..
(.:j- 07/ 
ELSEVIER 
Evolution of Clinical Intestinal Transplantation: Improved Outcome 
and Cost Effectiveness 
K.M. Abu-Elmagd, J. Reyes, J.J. Fung, G. Mazariegos, J. Bueno, C. Janov, J. Colangelo, A. Rao, 
A. Demetris, and T.E. Starzl 
I N PREVIOUS REPORTS we identified several risk 
factors that significantly affected patient and graft sur-
vival.!.:! Of these. four were major Immunologic risk factors: 
the number of intestinal allograft rejections. high blood FK 
506 levels. high dose steroid requirements. and the need for 
adjunct OKT3 therapy. The remaining significant risk fac-
tors were the operative and cold ischemia times. number of 
previous abdominal surgeries. cytomegaloviral (CMV) and 
post-transplant Iymphoproliferative diseases. To decrease 
the immunosuppressive requirements and improve survival 
outcome. we declared a I year moratOrIum in 1994. pending 
the results of extensive clarifying investigations bv Murase 
et al in rats:1 When the p~og;am reopened. ~o major 
changes in management strategy were instituted. One was 
an attempt to avoid, when possible. the transplantation of 
organs from CMV-positive donors to C:'1V-negative recip-
ients. The second change was to give perioperative adjunct 
donor bone marrow when this was available. in order to 
take advantage of the more tolerogenic profile of bone 
marrow cells compared to that of the IIltestinal passenger 
leukocytes:1- o Other adopted strategies were careful pa-
tient selection. exclusion of the cnlon from the intestinal 
allograft. and monitoring of Epstein-Barr virus (EBV) 
infection by serial quantitative EBV polymerase chain 
reaction (peR) measurements. 
MATERIALS AND METHODS 
We report here our overall long-term results With 115 intestmal 
transplantation in 109 consecutive pallents that were transplanted 
over S years. Of these b4 ER9r~F were children and 45 (41 '.''') were 
adults. The causes of intestinal failure were short gut syndrome 
(SGS) in 119 Epl~FK dysmotility syndrome in II (10','",). intestinal 
neoplasm in 0 (0%). and enterocytc dvsfunction in 3 (3%). The 
leading causes of SGS were vascular occlUSion. Crohn's disease. 
and trauma in adults and volvulus, ga~troschisisK atresia and 
necrotizing enterocolitis in children. The intestlIlc was engrafted 
alone (n 43). or as part of a compOSite gratt (n = 72). before and 
after the moratorium. All of the is()lated intesllnal recipients were 
sutferin1! from frequent ccntralllIlc SCpSIS. vamshing central venous 
access. and reversihle tOlal parenteral nutrition (TPN) Induced 
hepatlc dvstunctlon. The d()n()rs .... ere all ABO identical and liLA 
histolI1cllmpatlhlc. The ivmphllcvtotoxic crossmatch was posltlve 1I1 
14 paucrns. :"<,, attempts V'l're made to alter the graft Ivmpllllrc-
ticular tissue with antllvmph()cvte preparations or other modalities. 
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Of the last 55 recipients. 23 were infused with bone marrow. the 
distinction from the other 32 being the willingness of the donor 
family to permit the extra procurement procedure. The surgical 
techniques of the donor and recipient operation and details of bone 
marrow augmentation are fully described elsewhere.7- lO 
The management of the intestinal allograft recipients is fully 
described elsewhere. 11 The immunosuppressive therapy was based 
on FK 506 and prednisone. Cyclophosphamide was given to 23 
patients after the moratorium at a dose of 2 to 3 mg/kgld for 4 
weeks and then switched to mycophenolate mofetil (15 to 30 
mgJkgJd) or azathioprine. In a few cases. azathioprine was given as 
a third drug from the outset. The level of mamtenance immuno-
suppression was individualized and adjusted hased on the clinical 
course of each patient with the intentlon to reduce the drug dosage 
and levels whenever pOSSible. Episodes of rejection were treated 
with adjustments of FK 506 dose and/or supplemental prednisone. 
OKT3 was given only as a rescue therapy. Upward dose adjust-
ments of mycophenolate mofetil. azathioprine. or steroids. were 
frequently needed to compensate for FK-506 dose reductions 
mandated hy FK 506-related adverse effects. Patient and graft 
survival curves were generated using the Kaplan-Meier method 
and group comparisons .... ere performed using the log-rank test. 
RESULTS 
Survival 
The overall cumulative patient survival is T2q at 1 year and 
-+~o/c at 5 years with a graft survival rate of M% and 40%. 
respectively. With a mean follow-up of ~KEF ::: 29 months 
(range. 1 to 94 months). 31 patients are alive with good 
nutrition heyond the third postoperative year and 18 are 
well he yond the 5-year mile stone. The survival benefits of 
intestinal transplantation has been hetter (P = .57) 
achieved among children compared to adults with the best 
outcome among patients he tween 2 and 17 years of age. in 
whom the 5-year cumulative survival rate was 68%. Al-
though hoth the isolated intestinal and composite visceral 
grafts had similar (P = .72) survival rates. the cumulative 
risk of graft loss due to rejection was significantly (P = .045) 
higher among the isolated intestine. The Kaplan-Meier 
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EVOLUTION OF INTESTINAL TRANSPLANTATION 
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graft survival curves stratified Jccording to the cause of 
intestinal failure are depicted in Figure I. The best survival 
rates have heen achieved among children with microvillus 
disease and gastroschisis and in adults with Crohn's disease 
and vascular thrombosis. Figure 2 ,hows the significant 
(P = .(4) improvement in intestinal allograft survival during 
the last four years (after the moratorium) with a cumulative 
rate of 65% at 4 years. Such an achie\ement reflects further 
refinement in operative techniques. immunomodulation. 
and postoperative management as descrihed above. 
Long-Term Rehabilitation 
Fifty-one (93%) of 55 current survivors are home. fully 
active. and completelv nIl TPN with full nutritional auton-
omy. These individuals have reported improved quality of 
life measures in comparison to TPN dependency. Two 
(3.5 r r) of the remaining four recipients require home 
parenteral nutrition because of dmmic graft dysmotility. 
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Fig 2. Graft survival before and after the 1994 moratorium. 
Fig 1. Graft survival according 
to the native intestinal disease. 
The other two (3.5%) patients are receiving partial intr,l-
venous support while recovering from a recent episode of 
moderate to severe rejection. :--10 clinical or histopathologic 
evidences of disease recurrence has been documented 
during the 8 years of follow-up. To date. no attempts have 
been made to electively wean any of the intestinal recipi-
ents. including the hone marrow augmented cases. off 
immunosuppression. 
Cost Analysis 
The avcrage cost of intestinal transplantation between 1990 
and 1994 was 5203.111 for the isolated intestine. $252..+53 
for the combined liver-intestine transplantation. and 
5284.-152 for the multivisceral procedure. This has been 
significant Iv reduced during the last -I years to an average of 
5132.285. S2l4.716. and S219.09K respectively. The use of 
intestinal transplant can he examined on a cost-effective-
ness basis. due to the availahility of chronic TPN as an 
alternative therapy I'm patients with irreversible gut failure. 
Based on Medicare data. the average yearly cost of TPN in 
1992 was more than 5150.000 per patient not including the 
cost of frequent hospitalization. medical equipment. and 
nursing care. 12 The total dollars spent on TPN are increas-
ing every year hecause of the vearlv increase in TPN cost 
and the cumulative increas..: llf the home and hospital 
hound qm~ population. Based on these data. intestinal 
transplantation hecomes eost-ctfectivc bv the second year 
;ltter transplantation. 
CONCLUSIONS 
I ntestinal transplantation has hecome a life-saving treat-
ment for pall..:nts with Irreyersihk intestinal failure who 
canllot he maintained on TP:--I. and a cost-effective therapy 
for pallents who still have the optllln of TPN. The long-term 
rehahilitalloll with all threc kinds of intestinal transplant 
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procedures is similar to that achieved with lung transplan-
tation l' (currently eligible for reimbursement by Medicare) 
and the other kinds of organ allografts. Therefore, it is 
justifiable, to consider intestinal transplantation as nonex-
perimental procedure that is eligible for reimbursement 
under Medicare, Medicaid, and other third party payers in 
the United States, Based on the results of our most recent 
preclinical trials (unpublished data), further improvement 
in patient and graft survival is greatly anticipated with 
further immune modulation strategies (graft cytoreduction) 
that can be added to the bone marrow augmentation 
protocoL 
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